FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382458651> ?p ?o ?g. }

• W4382458651 endingPage "81" @default.
• W4382458651 startingPage "76" @default.
• W4382458651 abstract "The large majority of patients with HER2-positive metastatic breast cancer (MBC) will eventually develop resistance to anti-HER2 therapy and die of this disease. Despite, relatively high levels of stromal tumor infiltrating lymphocytes (sTILs), PD1-blockade has only shown modest responses. Monalizumab targets the inhibitory immune checkpoint NKG2A, thereby unleashing NK- and CD8 T cells. We hypothesized that monalizumab synergizes with trastuzumab by promoting antibody-dependent cell-mediated cytotoxicity. In the phase II MIMOSA-trial, HER2-positive MBC patients were treated with trastuzumab and 750 mg monalizumab every two weeks. Following a Simon's two-stage design, 11 patients were included in stage I of the trial. Treatment was well tolerated with no dose-limiting toxicities. No objective responses were observed. Therefore, the MIMOSA-trial did not meet its primary endpoint. In summary, despite the strong preclinical rationale, the novel combination of monalizumab and trastuzumab does not induce objective responses in heavily pre-treated HER2-positive MBC patients." @default.
• W4382458651 created "2023-06-29" @default.
• W4382458651 creator A5000111147 @default.
• W4382458651 creator A5004696803 @default.
• W4382458651 creator A5009034623 @default.
• W4382458651 creator A5016015665 @default.
• W4382458651 creator A5016117849 @default.
• W4382458651 creator A5017136846 @default.
• W4382458651 creator A5021689879 @default.
• W4382458651 creator A5043980504 @default.
• W4382458651 creator A5045238785 @default.
• W4382458651 creator A5048535376 @default.
• W4382458651 creator A5066953061 @default.
• W4382458651 creator A5069200892 @default.
• W4382458651 creator A5071056994 @default.
• W4382458651 creator A5092354115 @default.
• W4382458651 date "2023-08-01" @default.
• W4382458651 modified "2023-10-15" @default.
• W4382458651 title "Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial" @default.
• W4382458651 cites W1882502102 @default.
• W4382458651 cites W2011922596 @default.
• W4382458651 cites W2096283457 @default.
• W4382458651 cites W2114101532 @default.
• W4382458651 cites W2148479421 @default.
• W4382458651 cites W2152811375 @default.
• W4382458651 cites W2515812752 @default.
• W4382458651 cites W2559561655 @default.
• W4382458651 cites W2559858344 @default.
• W4382458651 cites W2560406314 @default.
• W4382458651 cites W2766673799 @default.
• W4382458651 cites W2768089870 @default.
• W4382458651 cites W2771978163 @default.
• W4382458651 cites W2890298773 @default.
• W4382458651 cites W2895051293 @default.
• W4382458651 cites W2902856530 @default.
• W4382458651 cites W2903493397 @default.
• W4382458651 cites W2914643394 @default.
• W4382458651 cites W2942790586 @default.
• W4382458651 cites W2995808512 @default.
• W4382458651 cites W3016237517 @default.
• W4382458651 cites W3024962001 @default.
• W4382458651 cites W3043781639 @default.
• W4382458651 cites W3088588360 @default.
• W4382458651 cites W3203425221 @default.
• W4382458651 cites W4200219012 @default.
• W4382458651 cites W4226366051 @default.
• W4382458651 cites W4282961029 @default.
• W4382458651 cites W4283713242 @default.
• W4382458651 cites W4290790619 @default.
• W4382458651 cites W4318203686 @default.
• W4382458651 doi "https://doi.org/10.1016/j.breast.2023.06.007" @default.
• W4382458651 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37393645" @default.
• W4382458651 hasPublicationYear "2023" @default.
• W4382458651 type Work @default.
• W4382458651 citedByCount "0" @default.
• W4382458651 crossrefType "journal-article" @default.
• W4382458651 hasAuthorship W4382458651A5000111147 @default.
• W4382458651 hasAuthorship W4382458651A5004696803 @default.
• W4382458651 hasAuthorship W4382458651A5009034623 @default.
• W4382458651 hasAuthorship W4382458651A5016015665 @default.
• W4382458651 hasAuthorship W4382458651A5016117849 @default.
• W4382458651 hasAuthorship W4382458651A5017136846 @default.
• W4382458651 hasAuthorship W4382458651A5021689879 @default.
• W4382458651 hasAuthorship W4382458651A5043980504 @default.
• W4382458651 hasAuthorship W4382458651A5045238785 @default.
• W4382458651 hasAuthorship W4382458651A5048535376 @default.
• W4382458651 hasAuthorship W4382458651A5066953061 @default.
• W4382458651 hasAuthorship W4382458651A5069200892 @default.
• W4382458651 hasAuthorship W4382458651A5071056994 @default.
• W4382458651 hasAuthorship W4382458651A5092354115 @default.
• W4382458651 hasBestOaLocation W43824586511 @default.
• W4382458651 hasConcept C121608353 @default.
• W4382458651 hasConcept C126322002 @default.
• W4382458651 hasConcept C143998085 @default.
• W4382458651 hasConcept C167672396 @default.
• W4382458651 hasConcept C170493617 @default.
• W4382458651 hasConcept C203014093 @default.
• W4382458651 hasConcept C203092338 @default.
• W4382458651 hasConcept C2775930923 @default.
• W4382458651 hasConcept C2778468042 @default.
• W4382458651 hasConcept C2779786085 @default.
• W4382458651 hasConcept C530470458 @default.
• W4382458651 hasConcept C535046627 @default.
• W4382458651 hasConcept C71924100 @default.
• W4382458651 hasConcept C8891405 @default.
• W4382458651 hasConceptScore W4382458651C121608353 @default.
• W4382458651 hasConceptScore W4382458651C126322002 @default.
• W4382458651 hasConceptScore W4382458651C143998085 @default.
• W4382458651 hasConceptScore W4382458651C167672396 @default.
• W4382458651 hasConceptScore W4382458651C170493617 @default.
• W4382458651 hasConceptScore W4382458651C203014093 @default.
• W4382458651 hasConceptScore W4382458651C203092338 @default.
• W4382458651 hasConceptScore W4382458651C2775930923 @default.
• W4382458651 hasConceptScore W4382458651C2778468042 @default.
• W4382458651 hasConceptScore W4382458651C2779786085 @default.
• W4382458651 hasConceptScore W4382458651C530470458 @default.
• W4382458651 hasConceptScore W4382458651C535046627 @default.
• W4382458651 hasConceptScore W4382458651C71924100 @default.

• next